Table 1.

Drugs Included in the Screen

Drug	Target/Mechanism of Action	Clinical Trials Phase	References
Trabectedin	RNA Pol II, DNA-bound proteins, tumor microenvironment/multitarget DNA-damaging agent	III	Monk et al.36
CX-4945	Casein kinase 2, Cdc2-like kinases	Ib/II	Borad et al.37
Foretinib	C-MET, VEGFR2, TAM (TYRO, Axl, MERTK) receptors	II	Rayson et al.38
RG7112	MDM2–p53 interaction/p53 activator	I	Andreeff et al.39